Zolmitriptan

Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine[1][2].

Product Specifications

CAS Number

[139264-17-8]

Product Name Alternative

BW-311C90; 311C90

UNSPSC

12352005

Hazard Statement

H302, H371

Target

5-HT Receptor; Endogenous Metabolite

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Zolmitriptan.html

Purity

99.98

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1OC[C@H](CC2=CC3=C(NC=C3CCN(C)C)C=C2)N1

Molecular Formula

C16H21N3O2

Molecular Weight

287.36

Precautions

H302, H371

References & Citations

[1]G R Martin, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan) . Br J Pharmacol. 1997 May;121 (2) :157-64.|[2]Katherine C Murray, et al. Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol. 2011 Aug;106 (2) :925-43.